Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA7 | P43166 | 6/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436372 | 0.95 | CA1 (0.49) | CA1CA2CA7CA14CA12 | |
| SCHEMBL18491763 | 0.79 | DRD2 (0.47) | KDM4EADRA2AADRA2BDRD2ESR1 | |
| SCHEMBL23929169 | 0.77 | DRD2 (0.48) | CA2CA9DRD2 | |
| SCHEMBL3172431 | 0.77 | DRD4 (0.54) | CA1CA2CA7CA14CA12 | |
| Hydrochloric Acid SCHEMBL11448686 | 0.77 | CA1 (0.54) | CA1CA2CA7CA14CA12 | |
| Hydrochloric Acid SCHEMBL11456735 | 0.77 | CA1 (0.54) | CA1CA2CA7CA14CA12 | |
| SCHEMBL23395332 | 0.76 | MEN1 (0.50) | PRMT5WDR77DRD2ESR1ESR2 | |
| SCHEMBL21201480 | 0.76 | CARM1 (0.51) | PRMT5WDR77DRD2 | |
| SCHEMBL23395349 | 0.76 | ESR2 (0.55) | CA9PRMT5DRD2ESR1ESR2 | |
| SCHEMBL16389169 | 0.76 | DRD2 (0.41) | PRMT5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112969692-A | Bumetanide derivatives for the treatment of hyperhidrosis | 兹伦汀公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| WO-2019193159-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | SLC9A1, SLC9A3, SLC5A1 | CA1 3002/4885CA2 393/4885CA7 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.